Safety of Ultomiris during pregnancy
Official title: Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Run by Alexion Pharmaceuticals, Inc. · NCT06312644 · Data updated 2026-11-12
This study looks at how safe Ultomiris is for pregnant women and their babies to see if it causes any problems during pregnancy and breastfeeding.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 75 (estimated) |
| Sponsor | Alexion Pharmaceuticals, Inc. Industry-sponsored |
| Locations | 7 sites (Boston, Massachusetts and 6 other locations) |
| Status | Recruiting |
| Started | December 16, 2024 |
| Main results expected | July 11, 2034 |
| Study ends | July 11, 2034 |
| Registry record updated | April 16, 2026 |
| Trial ID | NCT06312644 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pregnant women who have been exposed to Ultomiris and have a qualifying medical condition.
✕Probably not a fit
Patients who are not pregnant or have not been exposed to Ultomiris will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather data on pregnancy outcomes and maternal complications in women exposed to Ultomiris during pregnancy and breastfeeding. It will assess both maternal health and the effects on the developing fetus and infant through the first year of life. The study will collect both prospective and retrospective data to provide a comprehensive understanding of the risks associated with Ultomiris exposure in these populations.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the safety of Ultomiris for pregnant women and their infants, potentially guiding treatment decisions.
How similar studies have gone: While studies on drug safety during pregnancy are common, this specific focus on Ultomiris exposure is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female participant must have a medically confirmed qualifying pregnancy (prospectively or retrospectively identified). * Participant informed consent (written or e-consent per local regulations or ethics committee requirements) must be obtained prior to the participant's enrollment. If the participant is a minor, consent must be obtained from the parent or legal guardian, with assent from the minor (as locally appropriate). * Willing to provide contact information for the participant. * Willing to authorize HCP(s) to release maternal and infant medical information to the study, upon request, if applicable to current local regulations. * Diagnosed with an indication for which Ultomiris is approved, based on HCP or medical records. * Exposed to Ultomiris at any point during the defined exposure window based on HCP or medical record documentation. (If exact exposure dates are unknown, the reporter must be able to specify or estimate trimester or timing of exposure \[prior to conception as LMP+14 days, or during breastfeeding\].) * Use of Ultomiris per local product information (i.e., United States Prescribing Information \[USPI\] or summary of product characteristics \[SmPC\]) Exclusion Criteria: * Participants who are unable to provide consent or assent (as locally appropriate) (e.g., diagnosed with severe psychiatric conditions or severe intellectual disabilities) will be excluded from this study
Where it's running
-
Research Site
Boston, Massachusetts, United States Recruiting -
Research Site
Paris, France Recruiting -
Research Site
Essen, Norte-Westfalia, Germany Recruiting -
Research Site
Rome, Italy Recruiting -
Research Site
Melbourne, Victoria, Australia Not yet recruiting -
Research Site
Seoul, South Korea Active not recruiting
Show 1 more location
-
Research Site
London, United Kingdom Active not recruiting
Study contacts
- Principal investigator: Sydney Williams — North American Coordinating Center (NACC)
- Study coordinator: Alexion Pharmaceuticals, Inc. (Sponsor)
- Email: clinicaltrials@alexion.com
- Phone: 1-855-752-2356
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide
This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.
-
Pelvic Floor Training and a Modified Lumbopelvic Belt for Symphysis Pubis Pain in Pregnancy
This study tests whether pelvic floor muscle training plus a modified lumbopelvic belt can reduce pain and improve function for pregnant women with symphysis pubis pain.
-
Effective Communication in VBAC Counseling
This study tests how clearly doctors and midwives explain VBAC options during prenatal visits and whether patients feel understood.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
Understanding congenital bone marrow failure and related disorders through a national network
This project tests whether people with rare inherited bone marrow failure syndromes or related conditions really have the underlying genetic causes, by collecting data and samples across multiple centers.
-
Compare spinal-epidural versus general anesthesia for babies after cesarean delivery
This trial tests whether the type of anesthesia used for cesarean delivery affects newborn hearing in babies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.